Tyrosine Kinase Inhibitors: all 10,744 studies that test it
Page 80 of 108. Open to participants first (1,949), then studies with results posted, then the rest; newest registration first within each.
- A Phase I Study of Anlotinib on Pharmacokinetics to Assess the Effect of High Fat Diet in Advanced Cancer PatientsCompletedNCT02825563Phase 1
- Neo-adjuvant Trial With AZD9291 in EGFRm+ Stage IIIA/B NSCLCStatus unknownNCT02824952Phase 2
- A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR MutationsStatus unknownNCT02824458Phase 3
- Treatment With AZD4547 for Recurrent Malignant Glioma Expressing FGFR-TACC Gene Fusion"CompletedNCT02824133Phase 1/2
- The Role of Icotinib in the Perioperative Treatment of IIIA - IIIB NSCLC Patients With EGFR MutationStatus unknownNCT02820116Phase 2
- MEDI4736 Combinations in Metastatic Renal Cell CarcinomaCompletedNCT02819596Phase 2
- TD-1473 for Active Ulcerative Colitis (UC)CompletedNCT02818686Phase 1
- Turmeric Anti-Inflammatory and Cell-Damage TrialCompletedNCT02815475Not applicable
- Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and PrednisoneWithdrawnNCT02815059Phase 1
- The Safety and Maximum Tolerated Dose of Axitinib in Combination With Radiotherapy for HCCCompletedNCT02814461Phase 1
- Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/AmplificationWithdrawnNCT02812693Phase 1/2
- Phase II Study of AZD9291 in Advanced Stage NSCLC With EGFR and T790M Mutations Detected in Plasma Ct-DNAStatus unknownNCT02811354Phase 2
- Bosutinib in Elderly Chronic Myeloid LeukemiaCompletedNCT02810990Phase 2
- A Study of Anlotinib in Patients With Hepatocellular CarcinomaStatus unknownNCT02809534Phase 2
- Ph II Nintedanib vs. Ifosfamide in Soft Tissue SarcomaTerminatedNCT02808247Phase 2
- Drug-Interaction Study to Evaluate the Effect of Rifampin, a Potent CYP3A4 Inducer, on the Systemic Exposure of Pacritinib in Healthy SubjectsCompletedNCT02807116Phase 1
- PK of Pacritinib in Patients With Mild, Moderate, Severe Renal Impairment and ESRD Compared to Healthy SubjectsCompletedNCT02807077Phase 1
- To Evaluate the Effect of Clarithromycin on the Systemic Exposure of Pacritinib in Healthy SubjectsCompletedNCT02807051Phase 1
- PTCy and Ruxolitinib GVHD Prophylaxis in MyelofibrosisCompletedNCT02806375Phase 1/2
- PRe-Operative Gefitinib in Resectable EGFR Mutation Positive Lung Cancer With Sector Sequencing for Biomarker DiscoveryCompletedNCT02804776Phase 2
- Investigate Absorption, Metabolism, Excretion, and Mass Balance of PacritinibCompletedNCT02803762Phase 1
- Icotinib Hydrochloride Cream in Patients With Mild to Moderate PsoriasisCompletedNCT02801435Phase 1
- The Effects of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of RegorafenibCompletedNCT02800330Phase 4
- Effect of Enteral Genistein Supplementation in SepsisStatus unknownNCT02796794Phase 4
- Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid LeukemiaWithdrawnNCT02791919Phase 1
- Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian CancerCompletedNCT02788708Phase 1
- Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI TherapyStatus unknownNCT02787447Phase 2
- Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid LeukemiaTerminatedNCT02782403Phase 1
- Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Non-squamous and Non-small Cell Lung CancerStatus unknownNCT02780778Phase 2/3
- Testing Lenvatinib in Patients With Adenoid Cystic CarcinomaActive, not recruitingNCT02780310Phase 2
- Next Generation Personalized Neuroblastoma TherapyTerminatedNCT02780128Phase 1
- A Study of Merestinib (LY2801653) in Healthy ParticipantsCompletedNCT02779738Phase 1
- A Study of AL2846 on Tolerance and PharmacokineticsStatus unknownNCT02779699Phase 1
- Conmana Combined With Thalidomide to Treat NSCLCStatus unknownNCT02778893Phase 4
- Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal CancersCompletedNCT02777710Phase 1
- Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CTP-543 in Healthy SubjectsCompletedNCT02777008Phase 1
- A Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in Refractory Metastatic GISTStatus unknownNCT02776878Not applicable
- Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic LeukemiaStatus unknownNCT02776605Phase 2
- A Clinical Trial of Maintenance Treatment of Apatinib in Advanced Gastric Cancer Patients Have Completed Postoprative Adjuvant ChemotherapyStatus unknownNCT02776527Phase 4
- A Study of Apatinib in Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and NeckStatus unknownNCT02775370Phase 2
- Docetaxel Versus Intercalated Erlotinib-docetaxel in Patients With Relapsed EGFR Wild Type, ALK Negative Non Squamous Cell CarcinomaTerminatedNCT02775006Phase 3
- Predictive Biomarkers of Biological Activity and Efficacy of Nilotinib on ZAK Target in Non-metastatic Colon CancerWithdrawnNCT02774512Early Phase 1
- A One-arm Exploratory Clinical Research Program Study of Apatinib in Advanced Metastatic Renal Cell Carcinoma Patients.Status unknownNCT02774200Phase 2
- A Study of Regorafenib in Refractory Advanced Gastro-Oesophageal CancerStatus unknownNCT02773524Phase 3
- A Study of Apatinib for Advanced Hepatocellular Carcinoma Patients After First-line Treatment FailureStatus unknownNCT02772029Phase 1/2
- Liquid Biopsy as a Tool to Evaluate Resistance to First and Third (AZD9291) (EGFR) (TKIs) in (EGFR) Mutant NSCLCStatus unknownNCT02771314Phase 2
- Osimertinib in First and Second Line Treatment of NSCLC Harboring EGFR Mutations From Circulating Tumor DNACompletedNCT02769286Phase 2
- Study of Apatinib Combined With Oral Vinorelbine in Metastatic HER2 Negative Breast CancerStatus unknownNCT02768415Phase 2
- eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) PatientsActive, not recruitingNCT02767804Phase 3
- SHR1020 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Squamous Non Small Cell Lung CancerTerminatedNCT02766140Phase 3
- Determine Pacritinib Pharmacokinetics in Impaired Hepatic Patients and Healthy SubjectsCompletedNCT02765724Phase 1
- Apatinib Dose Titration in Advanced or Metastatic Gastric CancerCompletedNCT02764268Not applicable
- A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP015K and MetforminCompletedNCT02760342Phase 1
- A Phase I Trial of HS-10241 in Solid TumorsCompletedNCT02759640Phase 1
- Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLLCompletedNCT02758665Phase 2
- Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)Status unknownNCT02758587Phase 1/2
- Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic LeukemiaActive, not recruitingNCT02756897Phase 2
- A Clinical Trial of Buparlisib and Ibrutinib in LymphomaCompletedNCT02756247Phase 1
- A Phase I Additional Study of Anlotinib on Tolerance and PharmacokineticsStatus unknownNCT02752516Phase 1
- Effect of COX-2 and EGFR Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective Randomized StudyStatus unknownNCT02748707Phase 2
- Sorafenib Combined With Aspirin to Prevent the Recurrence in High-risk Patients With Hepatocellular CarcinomaTerminatedNCT02748304Not applicable
- Gilotrif (Afatinib) in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or GefitinibCompletedNCT02747953Phase 2
- Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway AberrationsWithdrawnNCT02747797Phase 2
- Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With Sorafenib in Combination With IrinotecanWithdrawnNCT02747537Phase 2
- D-ALBA Frontline Sequential Dasatinib and Blinatumomab in Adult Philadelphia Positive Acute Lymphoblastic LeukemiaStatus unknownNCT02744768Phase 2
- Cryotherapy Combine Icotinib for Advanced NSCLC TreatmentCompletedNCT02744664Phase 4
- Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in LymphomaWithdrawnNCT02743546Phase 1
- Trial Ruxolitinib and Peg-interferon Alpha-2a Combination in Patients With Primary Myelofibrosis RUXOPegCompletedNCT02742324Phase 1/2
- Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR MutationStatus unknownNCT02737774Phase 2
- Study of CG200745 PPA in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic CancerStatus unknownNCT02737228Phase 1/2
- Safety and Efficacy of Saracatinib In Subjects With LymphangioleiomyomatosisTerminatedNCT02737202Phase 2
- Intracranial Activity of AZD9291 (TAGRISSO) in Advanced EGFRm NSCLC Patients With Asymptomatic Brain MetastasesStatus unknownNCT02736513Phase 2
- Use of Regorafenib in Recurrent Epithelial Ovarian CancerCompletedNCT02736305Phase 2
- A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell LymphomaWithdrawnNCT02735876Phase 3
- Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular CarcinomaStatus unknownNCT02733809Phase 4
- The Efficacy and Safety of Apatinib Combined With Etoposide in Heavily Pretreated Advanced Non-small Cell Lung CancerStatus unknownNCT02733107Phase 2
- Study of Apatinib in Patients With Differentiated Thyroid CancerCompletedNCT02731352Phase 2
- Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell LymphomaWithdrawnNCT02729961Phase 1/2
- First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid TumorsCompletedNCT02729298Phase 1
- A Study of Second-line Treatment With Apatinib After TACE in Advanced Hepatocellular Carcinoma PatientsStatus unknownNCT02727309Phase 1/2
- Apatinib as Second-line Treatment of Advanced Pancreatic CancerStatus unknownNCT02726854Phase 2
- High Dose Icotinib With Sequential SRS For NSCLC Patients Harboring EGFR Mutation With Brain MetastasesStatus unknownNCT02726568Phase 2
- Phase II Study Assessing the Efficacy and Safety of Lenvatinib for Anaplastic Thyroid CancerCompletedNCT02726503Phase 2
- Nanocurcumin for Prostate Cancer Patients Undergoing Radiotherapy (RT)Status unknownNCT02724618Phase 2
- Curcumin in Combination With 5FU for Colon CancerTerminatedNCT02724202Early Phase 1
- A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic LeukemiaCompletedNCT02723994Phase 2
- Pemetrexed and Erlotinib for Metastatic Colorectal CancerCompletedNCT02723578Phase 2
- Olmutinib (BI 1482694) ADME StudyCompletedNCT02722161Phase 1
- Study of TKI 258 in Combination With Xeloda and Oxaliplatin in Advanced Colorectal and Gastric CancerTerminatedNCT02720926Phase 1
- Safety, Tolerability, and Pharmacokinetics of a Single Oral Dose of SKI-O-703 in Healthy VolunteersCompletedNCT02717988Phase 1
- A Study of Tafetinib in Chinese Patients With Advanced Solid TumorStatus unknownNCT02717741Phase 1
- A Study of TAK-788 in Adults With Non-Small Cell Lung CancerActive, not recruitingNCT02716116Phase 1/2
- Thoracal Radiotherapy and TarcevaTerminatedNCT02714530Phase 2
- Efficacy of Rechallenge With Sunitinib in Metastatic Pancreatic Neuroendocrine Tumor Previously Failed to SunitinibCompletedNCT02713763Phase 2
- A Study of Intermittent Dosing Schedule of Imatinib in Patients With Tyrosine Kinase Inhibitor Refractory GISTsCompletedNCT02712112Phase 2
- A Study of Apatinib Mesylate (YN968D1) 1,000mg in Gastric Cancer Patient Failed to Standard TreatmentCompletedNCT02711969Phase 1
- Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal TherapyCompletedNCT02711007Phase 2/3
- Safety, Tolerability and Relative Bioavailability Study of BMS-986195 in Healthy SubjectsCompletedNCT02705989Phase 1
- Rociletinib Genomic Landscape in Non-small Cell Lung Cancer (NSCLC)WithdrawnNCT02705339Phase 2
- Tarceva With or Without Apatinib in the Advanced Lung AdenocarcinomaStatus unknownNCT02704767Phase 2